[go: up one dir, main page]

ES2186685T3 - Genes hibridos destinados para ser utilizados en la produccion de celulas t citotoxicas independientes de celulas t auxiliares. - Google Patents

Genes hibridos destinados para ser utilizados en la produccion de celulas t citotoxicas independientes de celulas t auxiliares.

Info

Publication number
ES2186685T3
ES2186685T3 ES94914020T ES94914020T ES2186685T3 ES 2186685 T3 ES2186685 T3 ES 2186685T3 ES 94914020 T ES94914020 T ES 94914020T ES 94914020 T ES94914020 T ES 94914020T ES 2186685 T3 ES2186685 T3 ES 2186685T3
Authority
ES
Spain
Prior art keywords
cells
lymphocyte
activated
stimulatory factor
citotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914020T
Other languages
English (en)
Inventor
Stephen D Lupton
James M Allen
Andrew L Feldhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ampliphi Biosciences Corp
Original Assignee
Targeted Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Genetics Corp filed Critical Targeted Genetics Corp
Application granted granted Critical
Publication of ES2186685T3 publication Critical patent/ES2186685T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE SUMINISTRAN VECTORES RECOMBINANTES QUE DAN UNA RESPUESTA PROLIFERATIVA DE LINFOCITOS ACTIVADOS, PRINCIPALMENTE LINFOCITOS T CITOTOXICOS, CON UNA INDEPENDENCIA AMINORADA DE LAS CELULAS Th. LOS VECTORES COMPRENDEN UNA REGION QUE CODIFICA UN POLIPEPTIDO DEL FACTOR ESTIMULATORIO OPERABLEMENTE UNIDO A UNA REGION DE CONTROL TRANSCRIPCIONAL HETEROLOGA. LA EXPRESION DEL POLIPEPTIDO DE FACTOR ESTIMULADOR A PARTIR DEL POLINUCLEOTIDO RECOMBINANTE EN UN LINFOCITO ACTIVADO OFRECE UNA RESPUESTA PROLIFERATIVA DE MENOR DEPENDENCIA A LAS CELULAS T{SUB, H} DEL LINFOCITO. CUANDO SE ACTIVA EL LINFOCITO MEDIANTE LA UNION DE SU ANTIGENO LA REGION DE CONTROL TRANSCRIPCIONAL PROVOCA LA TRANSCRIPCION DE LA REGION DE CODIFICACION DEL FACTOR ESTIMULADOR. LAS CELULAS QUE CONTIENEN EL VECTOR, PARTICULARMENTE CTLS, SON UTILES EN INMUNOTERAPIA.
ES94914020T 1993-04-06 1994-04-04 Genes hibridos destinados para ser utilizados en la produccion de celulas t citotoxicas independientes de celulas t auxiliares. Expired - Lifetime ES2186685T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4453993A 1993-04-06 1993-04-06

Publications (1)

Publication Number Publication Date
ES2186685T3 true ES2186685T3 (es) 2003-05-16

Family

ID=21932948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914020T Expired - Lifetime ES2186685T3 (es) 1993-04-06 1994-04-04 Genes hibridos destinados para ser utilizados en la produccion de celulas t citotoxicas independientes de celulas t auxiliares.

Country Status (11)

Country Link
US (2) US5874556A (es)
EP (1) EP0693940B1 (es)
JP (1) JPH08510901A (es)
AT (1) ATE227772T1 (es)
AU (1) AU695615B2 (es)
CA (1) CA2159898A1 (es)
DE (1) DE69431715T2 (es)
DK (1) DK0693940T3 (es)
ES (1) ES2186685T3 (es)
PT (1) PT693940E (es)
WO (1) WO1994022489A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063652A1 (en) * 1988-03-21 2004-04-01 Jolly Douglas J. Combination gene delivery vehicles
US6083751A (en) * 1994-11-01 2000-07-04 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
WO1996033282A2 (en) * 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
AU780231B2 (en) * 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1461422A4 (en) * 2001-11-22 2005-11-16 Medigenes INTERLEUKIN 2 GENE TRANSFERRED LYMPHOKIN ACTIVATED KILLER CELLS
US7381405B2 (en) * 2002-10-15 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
WO2004034789A1 (en) * 2002-10-15 2004-04-29 The Government Of The United States Of America Represented By The Secretary Department Of Health And Human Services Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
NZ555830A (en) * 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20140037599A1 (en) * 2012-08-03 2014-02-06 The Trustees Of The University Of Pennsylvania Compositions and Methods of Treating T Cell Deficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184050T1 (de) * 1990-09-28 1999-09-15 Immunex Corp Verfahren zur herstellung th-unabhängiger zytotoxischer t-zymphozyten
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
WO1995007358A1 (en) * 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes

Also Published As

Publication number Publication date
JPH08510901A (ja) 1996-11-19
PT693940E (pt) 2003-03-31
US5874556A (en) 1999-02-23
AU695615B2 (en) 1998-08-20
DK0693940T3 (da) 2002-12-16
AU6624894A (en) 1994-10-24
US6593124B1 (en) 2003-07-15
ATE227772T1 (de) 2002-11-15
DE69431715D1 (de) 2002-12-19
CA2159898A1 (en) 1994-10-13
EP0693940B1 (en) 2002-11-13
WO1994022489A1 (en) 1994-10-13
EP0693940A1 (en) 1996-01-31
EP0693940A4 (en) 1998-08-19
DE69431715T2 (de) 2003-07-03

Similar Documents

Publication Publication Date Title
ES2186685T3 (es) Genes hibridos destinados para ser utilizados en la produccion de celulas t citotoxicas independientes de celulas t auxiliares.
AU578011B2 (en) A polycistronic expression vector for vertebrate cells
IE812297L (en) Stabilising transformed cells
ES2006383A6 (es) Procedimiento para la preparacion de vectores hibridos de levadura comprendiendo promotores de levadura represibles con los lugares de actuacion aguas arriba del gen ph05 de levadura.
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
IE831211L (en) Cloning vectors for expression of exogenous protein
WO1991011525A3 (en) Vaccines
DE69738514D1 (de) Verbesserte expressionsvektoren
BR0214350A (pt) Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
GR3026230T3 (en) Expression of recombinant polypeptides with improved purification
ATE87974T1 (de) Rekombinante dna-expressionsvektoren und dnazusammensetzungen, die isopenicillin-n-synthetase aus penicillium chrysogenum codieren.
HUP9902438A2 (hu) Parapoxvírus vektorok
IE801137L (en) Dna transfer vector
EP0365525A4 (en) Lymphocyte inhibition by hla peptides
ES8802585A1 (es) Un procedimiento para la preparacion de un plasmido que codifica isopenicilina n sintetasa
AU566133B2 (en) New polypeptide from thymus glands
ES2075068T3 (es) Procedimiento de preparacion de una proteina mediante levaduras que utiliza un sistema inducible, vectores y cepas transformadas correspondientes.
ES2134760T3 (es) Polipeptido saf, gen, promotor y uso para la expresion en streptomyces.
EP0271003A3 (en) Expression vectors
EP0105521A3 (en) Novel dna, microorganism transformed therewith and use thereof
Geuder et al. MG-associated thymoma-protein with an AChR-epitope. Molecular genetic characterization by sequence analysis of the cDNA
DE50113411D1 (de) Neue humane Androgenrezeptor-Varianten
JPS5695971A (en) Strong adhesive bonding of article
ES2088371B1 (es) Procedimiento para la produccion en forma recombinante de antigenos de la glicoproteina ge de herpesvirus bovino tipo 1 y su uso en la diferenciacion serologica entre animales infectados y animales vacunados.